Ticker Details
Aurinia Pharmaceuticals Inc Aurinia Pharmaceuticals Inc is a clinical stage pharmaceutical company. The firm is engaged in the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis.
IPO Date:	September 1, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.27 | 3.09%
Avg Daily Range (30 D):	$0.36 | 2.17%
Avg Daily Range (90 D):	$0.34 | 2.20%

Institutional Daily Volume
Avg Daily Volume:	1.71M
Avg Daily Volume (30 D):	1.49M
Avg Daily Volume (90 D):	1.16M

Trade Size
Avg Trade Size (Sh.):	162
Avg Trade Size (Sh.) (30 D):	80
Avg Trade Size (Sh.) (90 D):	73

Institutional Trades
Total Institutional Trades:	2,742
Avg Institutional Trade:	$1.35M
Avg Institutional Trade (30 D):	$3.13M
Avg Institutional Trade (90 D):	$2.36M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.45M
Avg Closing Trade (30 D):	$3.75M
Avg Closing Trade (90 D):	$2.63M
Avg Closing Volume:	131.78K

News

Apr 10, 2026 @ 8:59 AM 7MM Systemic Lupus Erythematosus and Lupus Nephrit... Source: Researchandmarkets.Com

Jan 8, 2025 @ 8:35 PM New American College of Rheumatology Guidelines fo... Source: Spherix Global Insights

Oct 2, 2024 @ 1:48 PM Corporate and Individual Donations Provide Much-Ne... Source: American Kidney Fund

Jun 17, 2024 @ 8:46 AM Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump... Source: Zacks Equity Research

May 7, 2024 @ 1:55 PM How Much Upside is Left in Aurinia (AUPH)? Wall St... Source: Zacks Equity Research

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$2.26	$.26	$1.6
Diluted EPS	$2.17	$.25	$1.53
Revenue	$298.3M	$77.71M	$77.11M
Gross Profit	$267.7M	$71.2M	$68.32M
Net Income / Loss	$298.21M	$34.36M	$210.79M
Operating Income / Loss	$124.49M	$41.42M	$33.24M
Cost of Revenue	$30.6M	$6.51M	$8.8M
Net Cash Flow	$-25.42M	$-39.21M	$7.02M
PE Ratio

Splits
Oct 23, 2013	1:50